Yield10 Bioscience Announces Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
Yield10 Bioscience, Inc. (YTEN) Reports Q2 Loss of $0.24
August 9, 2018 4:06 PM EDTYield10 Bioscience, Inc. (NASDAQ: YTEN) reported Q2 EPS of ($0.24).
A key highlight of the second quarter is the completion of planting for our 2018 field tests of C3003, said Oliver P. Peoples, Ph.D., President and Chief Executive Officer of Yield10 Bioscience. The results of these field tests will allow us to set the direction and priorities for the next steps in the evaluation and development of C3003 as a potentially valuable new... More
